[30P-am338S] Effect of discontinuing antihypertensive medication on blood pressure in elderly patients with polypharmacy

○Riku Ono¹, Hayato Suzuki¹, Masaki Kikuta¹, Miu Itabashi¹, Honoka Nagasaka¹, Hoshi Utsuda¹, Kazuma Miyagawa¹, Garyu Takeda¹, Takuto Kubo¹, Takumi Hoshino¹, Saki Takahashi¹, Kazuo Hara², Yorinobu Usui², Maho Taguchi¹, Hiroaki Yamada¹ (1. Yokohama University of Pharmacy, 2. Wakaba Co.)

[30P-am339] Research on promotion of development of academia-discovered drugs -Analysis of current status of approved drugs in Japan, the US and EU and comparison of their environments

○Taisuke Osakabe^1,2, Naomi Nagai¹ (1. Regulatory Science Laboratory, Research Institute of Pharmaceutical Sciences, Musashino University, 2. Daiichi Sankyo Co., Ltd. )

[30P-am340] Development of a novel off-target evaluation method to ensure the safety of targeted protein degradation drug

○Nobumichi Ohoka¹, Takenori Yamamoto¹, Tokuyuki Yoshida¹, Takao Inoue¹ (1. NIHS)

[30P-am341S] The Impact of the enforcement of Guidelines for Prescription Drug Marketing Information Provision on information provision by pharmaceutical companies to medical institution

○Aya Toma¹, Shinichi Watanabe², Shingo Kondo^1,3, Hiroki Iwata^1,3, Noriko Kobayashi^1,3, Katsunori Yamaura^1,3 (1. Keio Univ Faculty Pharm, 2. Teikyo Heisei Univ Faculty Pharm, 3. Keio Univ Commun Pharm)

[30P-am342S] Survey on Personal Transaction of Pharmaceuticals via SNS

○RUOYU ZHANG¹, Kazuko Kimura², Naoko Yoshida^2,3 (1. x, 2. x1, 3. x2)

[30P-am343S] Quality evaluation of the Japanese Pharmacopoeia Gentamicin sulfates by HPLC-MS/MS

○Akiho Maeda¹, Chisato Takahashi¹, Muneshige Tokugawa¹, Yumiko Kubota², Mari Matsui³, Toshifumi Konda³, Yukari Nakagawa⁴, Sachiyo Yoneda⁴, Yuri Mori⁴, Ryuichi Sawa², Satowa Suzuki³, Keiko Maekawa¹ (1. Doshisha Women's College of Liberal Arts, 2. Institute of Microbial Chemistry, 3. NIID, 4. PMRJ)

[30P-am344] Survey on samples for performance evaluation of nucleic acid amplification tests permitted for emergency use

○Yoshinori Tsukumo¹, Takao Inoue¹ (1. NIHS)

[30P-am345] Evaluation of Dosing Optimization for Rivaroxaban in the Japanese: A Study Using Databases and PK/PD Models

○akira okada^1,2, Kairi Sasaki¹, Yuki Saishoji¹, Kyoko Hatakeyama¹, Ouka Saeki¹, Hikaru Satake¹, Shoji Sera^1,2, Naomi Nagai^1,2 (1. Fac. Pharm., Musashino Univ., 2. Res. Ins. Pharm. Sci., Musashino Univ.)

[30P-am346S] Comparison of DTx products approved/recommended by regulatory authorities inside/outside Japan

○Takashi Hosono^1,2, Masuo Kondoh¹ (1. Grad. Sch. Pharm. Sci., Osaka Univ. , 2. NS Pharma, Inc. )

[30P-am347] Skin permeability evaluation and sterilization necessity verification in coated MNA

○Yusuke Okamoto¹, Chie Hasegawa¹, Hirotoshi Akane¹, Takeshi Toyoda¹, Ying-shu Quan², Fumio Kamiyama², Kumiko Ogawa¹, Kenichi Izutsu¹, Eiichi Yamamoto¹, Yusuke Nomura¹ (1. Nat. Inst. Health Sci., 2. CosMED Pharm.)

[30P-am348] Research on health and hygiene issues in personal import of pharmaceuticals via the Internet- Trial purchase survey of forziga, dextromethorphan and diphenhydramine tablets -

○Shu Zhu^1,3, Yuri Mitani², Ryo Matsushita², Kazuko Kimura³, Naoko Yoshida^1,2,3 (1. ai@ku, Kanazawa Univ., 2. Inst. Med. Pharm. Health Sci., Kanazawa Univ., 3. Med. Sec. Workshop)

[30P-am349] Examination of BBB maturity evaluation index aimed at the quality control of BBB-MPS

○yukari shigemoto-mogami¹, Kimiko Nakayama-Kitamura¹, Tomomi Furihata², Michiya Matsusaki³, Daiju Yamazaki¹, Seiichi Ishida^1,4, Kaoru Sato¹ (1. NIHS Divi. Pharmacol., 2. Tokyo Univ. Pharm. Life Sci., Divi. Pharm., 3. Grad. Sch. Eng., Osaka Univ., 4. Grad. Sch. Eng., Sojo Univ.)

[30P-am350] Comparison of adverse events between COVID-19 and other vaccines: Analysis of the FDA Adverse Event Reporting System (FAERS) and the Japanese Adverse Drug Event Report Database (JADER).

○YUKO ICHIKI¹, TAKEHIRO KAWASHIRI², KEISUKE MINE², KOHEI MORI², DAISUKE KOBAYASHI², TAKAO SHIMAZOE², NOBUHIRO NISHIMURA¹ (1. Grad. Sch. Pharm. Sci., International University of Health and Welfare at Fukuoka, 2. Grad. Sch. Pharm. Sci., Kyushu Univ.)

[30P-am351] Development of the visual inspection method for detecting falsified medicines obtained by personal import via the Internet

Shoei Maeda¹, Kazuko Kimura², ○Naoko Yoshida^1,2,3 (1. Inst. Med. Pharm. Health Sci., Kanazawa Univ., 2. Medicines Security Workshop, 3. ai@ku, Kanazawa Univ.)

[30P-am352] Evaluation of peptide-related impurities from nonstandard cyclic peptide by reversed phase chromatography

○Hashii Noritaka¹, Yoko Hiruta¹, Takashi Misawa¹, Nobumichi Ohoka¹, Takuo Suzuki¹, Yosuke Demizu¹, Akiko Watabe Ishii¹ (1. Natl. Inst. Health Sci.)

[30P-am353] Perturbation of gene expression by impurities in oligonucleotide therapeutics

○Yasunori Uchida¹, Tokuyuki Yoshida¹, Emi Saito², Hirokazu Nankai², Kazuya Ishida³, Yumi Akahori³, Kaoru Karasawa⁴, Chie Inagaki⁴, Noriyuki Iwasaki⁴, Daisuke Higo⁵, Kentaro Takahara⁵, Junji Kawakami⁶, Satoshi Obika⁷, Takao Inoue¹ (1. NIHS, 2. Ajinomoto Bio-Pharma Services GeneDesign, 3. CERI, 4. SCIEX, 5. Thermo Fisher Scientific, 6. FIRST, Konan Univ., 7. Grad. Sch. Pharm. Sci., Osaka Univ.)

[30P-am354] Assessment of detection capability of anti-HCP antibody utilized in HCP-ELISA using LC/MS

○Masashi Hyuga¹, Masaki Isogai^1,2, Aguri Itoh^1,2, Akiko Ishii-Watabe¹ (1. Natl. Inst. Health Sci., 2. Meiji Pharm. Univ.)

[30P-am355] Study about the components of hydrogel scaffold for the human 3D network blood-brain barrier microphysiological system - The essential roles of collagen microfiber -

○Kimiko Kitamura-Nakayama¹, Yukari Mogami-shigemoto¹, Marie Piantino², Tomomi Furihata³, Michiya Matsusaki², Daiju Yamasaki¹, Seiichi Ishida⁴, Kaoru Sato¹ (1. Phar., NIHS, 2. Grad. Sch. Eng., Osaka Univ., 3. Pharm., Tokyo Univ. Pharm. Life sci., 4. Biotech Life sci., Sojo Univ.)

[30P-am356S] Efficacy and safety of new class disease-modifying anti-rheumatic drugs: Bayesian and frequentist network meta-analysis

○Linfeng Liu¹, Mayu Onishi¹, Yuka Yoshii¹, Kaori Ambe¹, Toshiaki Makino¹, Masahiro Tohkin¹ (1. Grad. Sch. Pharm .Sci., Nagoya City Univ.)

[30P-am357S] Study on the assessment of eligibility for the criteria for medical necessity in the “Evaluation committee on unapproved or off-labeled drugs with high medical needs”

○Nozomi Omura¹, Saki Aino¹, Kazuhiro Matsui¹, Mamoru Narukawa¹ (1. Kitasato University School of Pharmacy)

[30P-am358S] Current state and issues related to drug lag of antineoplastic drugs in Japan : analysis including approved indications

○Toko Dobashi¹, Saki Aino¹, Mamoru Narukawa¹ (1. Grad. Sch. Pharm. Sci.,Kitasato Univ.)

[30P-am359] A New Simple Method for Estimation of Bad Taste of Medicines in Taste Sensors and Rats

○TOMOKO OGAWA¹, MAKI YONEKO², RYOKO ITO², KAZUHIRO ARAYA³, HIDEKAZU IKEZAKI³, JUN KOJIMA² (1. SUNDRUG CO.,LTD., 2. Medical and Health Resources Research Institute ,MHRRI, 3. Intelligent Sensor Technology, Inc.)

[30P-am360S] Selection of control compounds by machine learning for performance evaluation of safety assessment methods

○Yohei Ohto¹, Tadahaya Mizuno¹, Yasuhiro Yohsikai¹, Hiromi Fujimoto¹, Kaoru Sato², Hiroyuki Kusuhara¹ (1. Grad. Sch. Pharm. Sci., The University of Tokyo, 2. National Institute of Health Sciences)

[30P-am361S] Prediction of toxicity to the tubules using structural information of drugs by machine learning

○Hayato Kawazoe¹, Keiko Ogawa¹, Rumiko Hosoki¹ (1. Grad. Sch. Pharm. Sci., Ritsumeikan Univ.)

[30P-am362S] Investigation of concomitant medications associated with atorvastatin calcium hydrate induced rhabdomyolysis using the Japanese Adverse Drug Event Report database (JADER)

○Mai Okada¹, Keiko Ogawa¹, Chieri Fujino¹, Aika Tagami¹, Ayumi Noda¹, Rikuto Kawamura¹, Toshiya Katsura¹, Rumiko Hosoki¹ (1. Pharm. Sci., Ritsumeikan Univ.)

[30P-am363S] Investigation of drugs and underlying diseases affecting the development of HMG-CoA reductase inhibitor-induced rhabdomyolysis using the FDA Adverse Event Reporting System

○Shinya Fukumoto¹, Keiko Ogawa¹, Chieri Fujino¹, Aika Tagami¹, Ayumi Noda¹, Rikuto Kawamura¹, Toshiya Katsura¹, Rumiko Hosoki¹ (1. Pharm. Sci., Ritsueikan Univ.)

[30P-am364] Improvement of Loss on Drying Test in the Japanese Pharmacopoeia “Atropine Sulfate Hydrate”

○Fumiki Inoue¹, Nagisa Murao¹, Ayano Yamada¹, Kazuyuki Kiso¹, Iwao Takamuro¹, Yukari Nakagawa¹ (1. PMRJ)

[30P-am365] Evaluation of biodistribution of recombinant adenovirus vaccine in non clinical

○Yoichi Tanaka¹, Sayaka Hamano¹, Akiko Ishii¹, Yoshiro Saito¹, Ruri Hanajiri¹ (1. National Institute of Health Sciences)

[30P-am366] Regulatory science research on evaluation methods for full-length mRNA content of mRNA medicines

○Takenori Yamamoto¹, Tokuyuki Yoshida¹, Yasunori Uchida¹, Nobumichi Ohoka¹, Takuma Yamashita¹, Eriko Uchida¹, Takao Inoue¹ (1. National Institute of Health Sciences)

[30P-am367] Investigation of the impact of ICT and dispensing assistants in pharmacies on the shift to interpersonal services

○Toshinari Mitsuoka¹, Ryo Yokotani¹ (1. Hokkaido University of Science)

[30P-am368] Simple check for locomotive syndrome and survey on awareness and living situation - Involvement of community pharmacists in health maintenance of community residents-

○Haruka Shiraishi¹, Koji Tominaga¹, Mamiko Kai¹, Kazuhiko Ono¹, Keiko Haraguchi², Junichi Takagi², Taizou Tanaka², Tarou Kihara², Takashi Egawa¹ (1. Pharm.Sci.,Fukuoka Univ., 2. Fukuoka City Pharmaceutical Association)

[30P-am369] Japanese community pharmacists' perspectives on emergency contraceptive pill regulations

○Carmen Saito¹, Eriko Kobayashi¹ (1. Pharm. Sci., Josai International Univ.)

[30P-am370] Research of proper use of medicines including kampo or natural medicines (2nd report)

○KAZUTO Isuzugawa¹, KIMINA Ogura¹, AMIKO Moriyama¹, TETSUFUMI Takahashi¹, AKI Ito¹ (1. Yokohama Univ. Pharm.)

[30P-am371] Usage and Case Report of 3-month formulation of paliperidone palmitate long-acting injectable at Umibenomori Hospital

○kazuko hosogi¹ (1. Seikaen Medical Corporation Umibenomori Hospital Pharmacy Management Office)

[30P-am372] Questionnaire Survey to Community Pharmacists on Medication
Management Summary in Psychiatric Patients

○Minako Suenaga¹, Shigeru Ishida¹, Takahiro Kesamaru¹, Kimitaka Suetsugu¹, Akiko Kanaya¹, Rieko Grimm¹, Keiko Haraguchi², Junichi Takaki², Taro Kihara², Takeshi Hirota¹, Ichiro Ieiri¹ (1. Dept. of Pharmacy, Kyushu Univ. Hosp., 2. Fukuoka City Pharmaceut. Assoc.)

[30P-am373] Determination of imidazole dipeptides in seafood by liquid chromatography-tandem mass spectrometry with a pre-column derivatization reagent

○Mayu ONOZATO¹, Minori HORINOUCHI¹, Yuuki YOSHIBA¹, Tatsuya SAKAMOTO¹, Hiroshi SUGASAWA¹, Takeshi FUKUSHIMA¹ (1. Faculty of Pharmaceutical Sciences, Toho University)

[30P-am374S] Alterations in the concentration of serum thiol compounds in individuals with first-episode psychosis and those with at-risk mental state

○Tomokazu Furukawa¹, Mayu Onozato¹, Hiromi Tagata², Naohisa Tsujino^2,3, Hiroshi Imagawa², Tomoyuki Funatogawa², Naoyuki Naoyuki², Takahiro Nemoto², Takeshi Fukushima¹ (1. Faculty of Pharmaceutical Sciences, Toho University, 2. Faculty of Medicine, Toho University, 3. Saiseikai Yokohamashi Tobu Hospital)

[30P-am375] Introduction and evaluation of the usefulness of a new program for pharmacy students focusing on a cognitive behavioral therapy approach.

○Hatsuyo Maeda¹, Shunsuke Shirozu², Atsunobu Sagara², Tetsuro Yumoto³ (1. Nihon University, 2. Hoshi University, 3. Shonan University of Medical Sciences)

[30P-am376] A case of peripheral blood stem cell transplantation with HBV rebound after entecavir cessation:
Clinical implication of HBV core-related antigen

○Maki Ohkubo¹, Kuniaki Fukuda², Shigeru Chiba³, Masato Homma¹ (1. Dept. of Pharmacy, Univ. of Tsukuba HP, 2. Dept. of Gastroenterology, Univ. of Tsukuba HP, 3. Dept. of Hematology, Univ. of Tsukuba HP)

[30P-am377S] Relationship between singlet oxygen generation and cytotoxicity by nadifloxacin with UVA

○Yuki Kobayashi¹, Yumiko Iwase¹, Kentaro Yano¹, Takashi Kuwabara¹ (1. Yokohama Univ. Pharm.)

[30P-am378S] Quantification of organic acids by LC-MS/MS using a pre-column derivatization reagent for carboxyl group

○Mikoto Koishi¹, Maho Umino¹, Mayu Onozato¹, Tatsuya Sakamoto¹, Takeshi Fukushima¹ (1. Pharm.Sci., Toho University)

[30P-am379] Maina insurance card starts. Problems that have emerged at insurance pharmacies.

○Yasushi Terado¹, Naoya Tanaka², Yuki Shinohara¹, Seiichi Kato¹, Sumiko Kondo¹, Tomokazu Tanaka¹ (1. Pinokio Pharmacy, 2. Pinokio Pharma)

[30P-am380S] How to take and give herbal medicine - A study on how to take and when to take medicine

○Nodoka Yatsuda¹, Tsukasa Matsumoto^1,2 (1. Faculty of Pharmacy, Iryo Sosei University, 2. Graduate School of Life Science and Technology, Iryo Sosei University)

[30P-am381S] Examination of the CYP3A4 inhibitory activity of distilled water obtained from grapefruit peel

○Miyu Hayano¹, Wakaba Iwanaga¹, Keigo Tabata¹, Amika Miyasaka¹, Atsuko Kawachi², Gen-ichi Atsumi¹ (1. School of Pharma-Sciences, Teikyo University, 2. Japan Aroma Distillation Association)

[30P-am382S] Investigation of zinc transporter (ZIP) expression in small intestinal inflammation.

○Yuuki Otsuka¹, Saori Fuke², Taito Shinchi², Kazumi Iwata³, Kikuko Amagase^1,2 (1. Grad. Sch. Pharm. Sci., Ritsumeikan Univ., 2. Sch. Pharm. Sci., Ritsumeikan Univ., 3. Kyoto. Pref. Univ. of Medic.)

[30P-am383] Research on the safety of SGLT2 inhibitors for chronic heart failure in elderly patients and patients with decreased renal function

○Yuta Suzuki¹, Yuya Sakamoto¹, Noriaki Hidaka¹, Mamoru Tanaka¹ (1. Div. Pharm. Ehime Univ Hosp.)

[30P-am384] A case of peri-implantitis occurred during sublingual immunotherapy

○Shinako Ota¹, Motohiro Munakata², Shuichi Kiyohara², Kakei Ryu^3,4, Noriko Hida^1,3,4 (1. Grad. Sch. Pharm. Sci., Showa Univ., 2. Grad. Sch. Dent. Sci., Showa Univ., 3. SCRI, 4. SURAC)

[30P-am385] Current status of osteoporosis treatment for secondary fracture prevention in our hospital and the role of pharmacists.

○Yuko Tomita¹, Kazuyuki Hasegawa², Atsushi Tsuchiya² (1. Pharm. , 2. Orthopedic)

[30P-am386] Comparison of analgesic efficacy and safety of low-dose transdermal fentanyl and oral oxycodone in opioid-naïve patients with cancer pain

○Mariko Kawana^1,16, Akime Miyasato², Miyui Funato³, Keigo Nagatani⁴, Norifumi Suzuki⁵, Chiharu Onoda⁶, Hidenori Fujimoto⁷, Rintaro Ohno⁸, Ayuko Kusakabe⁹, Mio Kiribayashi¹⁰, Kazuyo Nakamura^11,16, Masayoshi Kondo^12,16, Ayumi Ozeki^13,16, Kousuke Okamoto^14,16, Hideya Kokubun^15,16 (1. Department of Pharmacy, Kameda General Hospital, 2. Department of Pharmacy, Tokyo Medical University Hospital, 3. Department of Pharmacy, Gifu University Hospital, 4. Palliative Care Center, Yao Municipal Hospital, 5. Department of Pharmacy, National Hospital Organization Sendai Medical Center, 6. Department of Pharmacy, Yaizu City Hospital, 7. Department of Pharmacy, Hiroshima Prefectural Hospital, 8. Department of Pharmacy, Saiseikai Utsunomiya Hospital, 9. Department of Pharmacy, Otaru General Hospital, 10. Department of Pharmacy, Tachikawa Hospital, 11. Department of Pharmacy, Shizuoka General Hospital, 12. Department of Pharmacy, Nippon Medical School Tama Nagayama Hospital, 13. Department of Pharmacy, Shonan General Hospital, 14. Faculty of Pharmaceutical Sciences, Hokuriku University, 15. Faculty of Pharmaceutical Sciences, Shonan University of Medical Sciences, 16. Research Support Committee, Japanese Society for Pharmaceutical Palliative Care and Sciences)

[30P-am387] A case report: Tenofovir Alafenamide-induced alopecia

○Shutaro Murakami^1,2 (1. Grad. Sch. Pharm. Sci. Meiji Pharmaceutical Univ, 2. Department of Pharmacy, Tama Medical Center )

[30P-am388] Survey of Patients Receiving Oral Therapeutic Drug for Novel Coronavirus Infections at Our Hospital

○Yutaka Ikeda¹, Yuri Kobayashi¹, Gou Takahashi¹, Takashi Ofuji², Daisuke Sawada¹ (1. Department of Pharmacy, National Center for Global health and Medicine Kohnodai Hospital., 2. Department of Respiratory medicine, National Center for Global health and Medicine Kohnodai Hospital.)

[30P-am389S] Literature review on SGLT2 inhibitors in patients with chronic heart failure.

○Yosuke Hayata¹, Miho Kageyama¹, Yusuke Hori¹ (1. Tokyo University of Pharmacy and Life Sciences)

[30P-am390S] Evaluation on the preventive effect of histamine H1 receptor antagonist on cisplatin-induced renal injury in rats

○Yuri Ishii¹, Hideyoshi Ohnuma¹, Takahiro Nagai¹, Narumi Fujimatsu¹, Miki Shoji¹, Rina Tokoyoda¹, Takayoshi Kosugi², Mitsutoshi Satoh¹ (1. Faculty of Pharmaceut. Sci., Meiji Pharmaceut. Univ.,, 2. Dept. of Pharm., Kanazawa Hosp.)

[30P-am391] A survey on awareness of herbal medicine among cancer and non-cancer patients

○Yoichi Ofusa¹, Takeshi Miyakawa¹, Susumu Takeuchi¹, Shiori Takitani¹, Takehiro Era¹, Yuki Ikkatai¹ (1. Nanohana pharmacy hokudaimae)

[30P-am392] Investigation of the tolerability and occurrence of adverse events at different doses after the introduction of Sacubitril Valsartan in patients with heart failure

○Michiru Nagao^1,2, Erika Iwasaki³, Mayumi Inamoto^1,2,3, Noriko Kohyama³, Mio Ebato⁴, Hiroshi Suzuki⁴, Mari Kogo³, Tomiko Sunaga^2,5 (1. Department of Pharmacy, Showa University Fujigaoka Hospital, 2. Department of Hospital Pharmaceutics, School of Pharmacy, Showa University, 3. Department of Clinical Pharmacy, Division of Pharmacotherapeutics, School of Pharmacy, Showa University, 4. Division of Cardiology, Department of Internal Medicine, Showa University Fujigaoka Hospital, 5. Department of Pharmacy, Showa University Dental Hospital)

[30P-am393] Examination of the risk of oversedation caused by risperidone administration to patients with delirium

○akihiro kondo¹, masayoshi hashimoto¹, yoko hirawata¹, yoshinori marutani¹, yuuji suzuki¹ (1. Department of Pharmacy, Tokai University Hospital)

[30P-am394] Risk factors for thrombocytopenia associated with teicoplanin: a retrospective observational study

○Yuki Shimizu¹, Kazuhiko Hanada², Takeaki Watanabe¹, Yuka Sasaki¹, Tomoka Yamazaki¹, Emi Komasaka¹, Keiko Kadota^1,3 (1. Department of Pharmacy, Tokyo Dental College Ichikawa General Hospital, 2. Department of Pharmacometrics and Pharmacokinetics, Meiji Pharmaceutical University, 3. Department of Clinical Pharmacy, Tokyo Dental College Ichikawa General Hospital)

[30P-am395S] Extraction of risk factors for treatment interruption of sacubitril valsartan

○Yuri Nakao¹, Yohei Nishio², Rina Bito², Kotoe Inoue², Tomoyuki Hirashita², Takahiro Hayashi¹ (1. Sch. Pharm. Sci., Kinjo Gakuin Univ., 2. Gifu Prefectural General Medical Center)

[30P-am396] Decrease in mycophenolic acid plasma level by sacubitril/valsartan in lupus nephritis patient: a case report

○Shunsuke Nashimoto¹, Masashi Miyamae², Issei Higuchi², Michihito Kono³, Maria Tada³, Tatsuya Atsumi³, Mitsuru Sugawara^1,2, Yoh Takekuma² (1. Fac. Pharm. Sci., Hokkaido Univ., 2. Dept. Pharm., Hokkaido Univ. Hosp., 3. Fac. Med.,/Grad. School of Med., Hokkaido Univ.)

Session information

[30P-am] Social Pharmacy

Authentication